Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
Amantadine suppressed severe levodopa-induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations. Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine-deficient metabolic disorders.
Furukawa
Yoshiaki
Y
Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division, Toronto, Ontario, Canada. yoshiaki_furukawa@camh.net
Filiano
James J
JJ
Kish
Stephen J
SJ
D000547:Amantadine / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002648:Child; D002819:Chorea / Q000150:complications / Q000188:drug therapy; D015259:Dopamine Agents / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology*; D006136:GTP Cyclohydrolase / Q000235:genetics*; D006579:Heterozygote; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy* / Q000235:genetics*; D010375:Pedigree; D010641:Phenotype; D017354:Point Mutation / Q000235:genetics*
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D007980:Levodopa; D000547:Amantadine; D006136:GTP Cyclohydrolase